Rasagiline in Parkinson's disease: A review based on meta-analysis of clinical data

Pharmacological Research

Volumn 74, Issue , 2013, Pages 78-86

  Mínguez Mínguez, Sara ^a   Del Pozo, Julián Solís García ^b   Jordán, Joaquín ^a,c  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^c Instituto de Investigación en Discapacidades Neurológicas UCLM   (Spain)

Author keywords

Azilect; Parkinson disease; Rasagiline; Unified Parkinson Disease Rating Scale

Indexed keywords

ENTACAPONE; LEVODOPA; PLACEBO; PRAMIPEXOLE; RASAGILINE; TYRAMINE;

AGE DISTRIBUTION; ATTENTION; BEHAVIOR DISORDER; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DAILY LIFE ACTIVITY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXECUTIVE FUNCTION; GASTROINTESTINAL DISEASE; HEART RATE; HUMAN; HYPERTENSION; HYPOSMIA; MENTAL FUNCTION; META ANALYSIS (TOPIC); MONOTHERAPY; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NONHUMAN; OFF TIME; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSON DISEASE QUALITY OF LIFE SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; RISK REDUCTION; SELF MONITORING; SIDE EFFECT; SLEEP DISORDER; SMELLING; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE;

AZILECT; PARKINSON DISEASE; RASAGILINE; UNIFIED PARKINSON DISEASE RATING SCALE;

ANTIPARKINSON AGENTS; HUMANS; INDANS; PARKINSON DISEASE;

EID: 84884734979     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.05.005     Document Type: Review

References (46)

1. A.H. Schapira, and P. Jenner Etiology and pathogenesis of Parkinson's disease Mov Disord 26 2011 1049 1055
2. K. Wirdefeldt, H.O. Adami, P. Cole, D. Trichopoulos, and J. Mandel Epidemiology and etiology of Parkinson's disease: a review of the evidence Eur J Epidemiol 26 Suppl. (1) 2011 S1 S58
3. W.H. Vogel, V. Orfei, and B. Century Activities of enzymes involved in the formation and destruction of biogenic amines in various areas of human brain J Pharmacol Exp Ther 165 1969 196 203
4. I.A. Paterson, B.A. Davis, D.A. Durden, A.V. Juorio, P.H. Yu, and G. Ivy Inhibition of mao-b by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain Neurochem Res 20 1995 1503 1510
5. J. Jankovic, and M. Stacy Medical management of levodopa-associated motor complications in patients with Parkinson's disease CNS Drugs 21 2007 677 692 (Pubitemid 47121793)
6. P. Solla, A. Cannas, F. Marrosu, and M.G. Marrosu Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (stalevo) Neuropsychiatr Dis Treat 6 2010 483 490
7. M.L. Tarrants, M.F. Denarie, J. Castelli-Haley, J. Millard, and D. Zhang Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence Am J Geriatr Pharmacother 8 2010 374 383
8. G. Gardian, and L. Vecsei Medical treatment of Parkinson's disease: today and the future Int J Clin Pharmacol Ther 48 2010 633 642
9. M.B. Youdim, A. Gross, and J.P. Finberg Rasagiline [n-propargyl-1r(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase b Br J Pharmacol 132 2001 500 506 (Pubitemid 32142364)
10. C.W. Olanow, O. Rascol, R. Hauser, P.D. Feigin, J. Jankovic, and A. Lang A double-blind, delayed-start trial of rasagiline in Parkinson's disease N Engl J Med 361 2009 1268 1278
11. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the presto study Arch Neurol 62 2005 241 248
12. Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: the tempo study Arch Neurol 59 2002 1937 1943
13. J.M. Rabey, I. Sagi, M. Huberman, E. Melamed, A. Korczyn, and N. Giladi Rasagiline mesylate, a new mao-b inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa Clin Neuropharmacol 23 2000 324 330 (Pubitemid 32047014)
14. J. Solís-García del Pozo, S. Mínguez-Mínguez, P.W.J. de Groot, and J. Jordán Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease Expert Opin Drug Saf 2013 10.1517/14740338.2013.790956 [in press]
15. N.J. Ives, R.L. Stowe, J. Marro, C. Counsell, A. Macleod, and C.E. Clarke Monoamine oxidase type b inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients Br Med J 329 2004 593
16. W.H. Jost, M. Friede, and J. Schnitker Indirect meta-analysis of randomized placebo-controlled clinical trials on rasagilina and selegiline in the symptomatic treatment of Parkinson's disease Basal Ganglia 2 2012 9
17. J.P.T. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions version 5.1.0 2011 The Cochrane Collaboration [updated march 2011]
18. O. Rascol, D.J. Brooks, E. Melamed, W. Oertel, W. Poewe, and F. Stocchi Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (largo, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial Lancet 365 2005 947 954 (Pubitemid 41071428)
19. C.W. Olanow, R.A. Hauser, J. Jankovic, W. Langston, A. Lang, and W. Poewe A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the adagio study): rationale, design, and baseline characteristics Mov Disord 23 2008 2194 2201
20. H.A. Hanagasi, H. Gurvit, P. Unsalan, H. Horozoglu, N. Tuncer, and A. Feyzioglu The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study Mov Disord 26 2011 1851 1858
21. A. Korchounov, Y. Winter, and W. Rossy Combined beneficial effect of rasagiline on motor function and depression in de novo pd Clin Neuropharmacol 35 2012 121 124
22. M.B. Stern, K.L. Marek, J. Friedman, R.A. Hauser, P.A. LeWitt, and D. Tarsy Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients Mov Disord 19 2004 916 923 (Pubitemid 39199258)
23. R.E. Wilson, L.C. Seeberger, D. Silver, A. Griffith, J.B. Conner, and Salzman P.M. Rasagiline time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment Neurologist 17 2011 318 324
24. F. Viallet, S. Pitel, S. Lancrenon, and O. Blin Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease Curr Med Res Opin 29 2013 23 31
25. T. Muller, J.A. Hoffmann, W. Dimpfel, and C. Oehlwein Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease J Neural Transm 120 2013 761 765
26. M.V. Alvarez, and P.M. Grogan Hyposmia in Parkinson's disease Psychiatry Clin Neurosci 66 2012 370
27. L. Zhang, Z. Zhang, Y. Chen, X. Qin, H. Zhou, and C. Zhang Efficacy and safety of rasagiline as an adjunct to levodopa treatment in chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial Int J Neuropsychopharmacol 2013 1 9
28. Parkinson Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease Arch Neurol 61 2004 561 566
29. K.M. Biglan, S. Schwid, S. Eberly, K. Blindauer, S. Fahn, and T. Goren Rasagiline improves quality of life in patients with early Parkinson's disease Mov Disord 21 2006 616 623 (Pubitemid 43840530)
30. R.A. Hauser, M.F. Lew, H.I. Hurtig, W.G. Ondo, J. Wojcieszek, and C.J. Fitzer-Attas Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease Mov Disord 24 2009 564 573
31. M.F. Lew, R.A. Hauser, H.I. Hurtig, W.G. Ondo, J. Wojcieszek, and T. Goren Long-term efficacy of rasagiline in early Parkinson's disease Int J Neurosci 120 2010 404 408
32. W.B. White, P. Salzman, and S.R. Schwid Transtelephonic home blood pressure to assess the monoamine oxidase-b inhibitor rasagiline in Parkinson disease Hypertension 52 2008 587 593
33. C.G. Goetz, S.R. Schwid, S.W. Eberly, D. Oakes, and I. Shoulson Safety of rasagiline in elderly patients with Parkinson disease Neurology 66 2006 1427 1429 (Pubitemid 43739656)
34. L. Elmer, S. Schwid, S. Eberly, C. Goetz, S. Fahn, and K. Kieburtz Rasagiline-associated motor improvement in pd occurs without worsening of cognitive and behavioral symptoms J Neurol Sci 248 2006 78 83 (Pubitemid 44647289)
35. J.A. deMarcaida, S.R. Schwid, W.B. White, K. Blindauer, S. Fahn, and K. Kieburtz Effects of tyramine administration in Parkinson's disease patients treated with selective mao-b inhibitor rasagiline Mov Disord 21 2006 1716 1721 (Pubitemid 44742203)
36. F. Stocchi, and J.M. Rabey Effect of rasagiline as adjunct therapy to levodopa on severity of off in Parkinson's disease Eur J Neurol 18 2011 1373 1378
37. E. Tolosa, and M.B. Stern Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease Eur J Neurol 19 2012 258 264
38. O. Rascol, C.J. Fitzer-Attas, R. Hauser, J. Jankovic, A. Lang, and J.W. Langston A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the adagio study): prespecified and post-hoc analyses of the need for additional therapies, changes in updrs scores, and non-motor outcomes Lancet Neurol 10 2011 415 423
39. C.E. Clarke, S. Patel, N. Ives, C. Rick, K. Wheatley, and R. Gray Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops Mov Disord 26 2011 1187 1193
40. A. Schrag, C. Sampaio, N. Counsell, and W. Poewe Minimal clinically important change on the unified Parkinson's disease rating scale Mov Disord 21 2006 1200 1207 (Pubitemid 44336608)
41. L.M. Shulman, A.L. Gruber-Baldini, K.E. Anderson, P.S. Fishman, S.G. Reich, and W.J. Weiner The clinically important difference on the unified Parkinson's disease rating scale Arch Neurol 67 2010 64 70
42. R.A. Hauser, and P. Auinger Determination of minimal clinically important change in early and advanced Parkinson's disease Mov Disord 26 2011 813 818
43. R. Deumens, A. Blokland, and J. Prickaerts Modeling Parkinson's disease in rats: an evaluation of 6-ohda lesions of the nigrostriatal pathway Exp Neurol 175 2002 303 317 (Pubitemid 34634286)
44. E. Tolosa, and C. Pont-Sunyer Progress in defining the premotor phase of Parkinson's disease J Neurol Sci 310 2011 4 8
45. P. Jenner, and J.W. Langston Explaining adagio: a critical review of the biological basis for the clinical effects of rasagiline Mov Disord 26 2011 2316 2323
46. J. Pagonabarraga, and J. Kulisevsky Rasagiline: effectiveness and protection in Parkinson's disease Rev Neurol 51 2010 535 541